周三，Canaccord Genuity维持对Regulus Therapeutics (NASDAQ:RGLS)股票的买入评级，目标价为$28.00。该公司的立场是在Victor Ambros和Gary Ruvkun因其在microRNA及其在基因调控中的作用方面的开创性工作而获得诺贝尔生理学或医学奖之后做出的。 这一科学认可强调了Regulus正在开发的抗miRNA-17产品的潜力，该产品目前 ...

Canaccord Genuity Group Inc. says it has named former RBC executive Nadine Ahn as deputy chief financial officer, with the ...

Canaccord Genuity Group Inc. appoints Nadine Ahn as Deputy CFO, with plans for her to transition to CFO in 2025.

Ahn, who will take over from incumbent Don MacFayden at the country’s largest independent investment dealer, was dismissed ...

Canaccord Genuity Group named Nadine Ahn as deputy chief financial officer. With the appointment, Ahn is set to succeed the Vancouver financial-services company's current CFO, Don MacFayden, who ...

Gilmour’s expected to join Argonaut in late January as a member of the firm’s senior leadership team and become a “meaningful” shareholder.

CNW/ - Canaccord Genuity Group Inc. (TSX: CF) (the "Company") is pleased to announce the appointment of Nadine Ahn as Deputy Chief Financial ...

Canaccord Genuity Group Inc., the Vancouver-based investment bank, is dismantling its fixed-income emerging markets business, ...

Phoenix-based 4Front Ventures Corp. (CSE: FFNT) (OTCQB: FFNTF) is making strategic moves to better position itself ...

Canaccord Genuity Group has completed its purchase of Cambridge-headquartered Cantab Asset Management, via its wealth ...

George Gianarikas, Canaccord Genuity analyst, joins CNBC's 'Squawk on the Street' to discuss what he's looking for at Tesla's ...

Analysts at Canaccord Genuity lowered their target price on agricultural business Wynnstay from 520.0p to 470.0p on Friday, ...